A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the departments of ophthalmology and biomedical engineering, to play a pivotal ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...

Liver cells are indispensable for research—for drug testing, to better understand diseases such as hepatitis, fatty liver, cirrhosis, or liver cancer and for development of future cell therapies.

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...